Shots: Post EMA’s ODD, A4250 has received FDA’s ODD following its P-III study assessing A4250 in patients with Alagille syndrome, biliary atresia and primary biliary cholangitis (PBC) FDA has granted […]readmore
Tags : Drug Candidate